Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
169.13
+1.25 (0.74%)
At close: Jan 21, 2026, 4:00 PM EST
169.16
+0.03 (0.02%)
After-hours: Jan 21, 2026, 4:00 PM EST
Jazz Pharmaceuticals Revenue
Jazz Pharmaceuticals had revenue of $1.13B in the quarter ending September 30, 2025, with 6.74% growth. This brings the company's revenue in the last twelve months to $4.16B, up 4.14% year-over-year. In the year 2024, Jazz Pharmaceuticals had annual revenue of $4.07B with 6.12% growth.
Revenue (ttm)
$4.16B
Revenue Growth
+4.14%
P/S Ratio
2.46
Revenue / Employee
$1,484,940
Employees
2,800
Market Cap
10.28B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.07B | 234.75M | 6.12% |
| Dec 31, 2023 | 3.83B | 174.83M | 4.78% |
| Dec 31, 2022 | 3.66B | 565.14M | 18.26% |
| Dec 31, 2021 | 3.09B | 730.67M | 30.91% |
| Dec 31, 2020 | 2.36B | 201.81M | 9.34% |
| Dec 31, 2019 | 2.16B | 270.84M | 14.32% |
| Dec 31, 2018 | 1.89B | 272.23M | 16.82% |
| Dec 31, 2017 | 1.62B | 130.72M | 8.79% |
| Dec 31, 2016 | 1.49B | 163.17M | 12.32% |
| Dec 31, 2015 | 1.32B | 151.93M | 12.95% |
| Dec 31, 2014 | 1.17B | 300.45M | 34.44% |
| Dec 31, 2013 | 872.42M | 286.44M | 48.88% |
| Dec 31, 2012 | 585.98M | 313.70M | 115.21% |
| Dec 31, 2011 | 272.28M | 98.50M | 56.68% |
| Dec 31, 2010 | 173.78M | 45.33M | 35.29% |
| Dec 31, 2009 | 128.45M | 60.94M | 90.26% |
| Dec 31, 2008 | 67.51M | 2.21M | 3.39% |
| Dec 31, 2007 | 65.30M | 20.45M | 45.58% |
| Dec 31, 2006 | 44.86M | 23.41M | 109.20% |
| Dec 31, 2005 | 21.44M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
JAZZ News
- 8 days ago - Jazz Pharmaceuticals plc (JAZZ) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 9 days ago - Boehringer Ingelheim announces clinical collaboration with Jazz Pharmaceuticals to advance HER2-targeted therapy in breast cancer - GlobeNewsWire
- 12 days ago - Jazz Pharmaceuticals plc (JAZZ) Discusses HERIZON-GEA-01 Phase III Trial Results for Zanidatamab in HER2+ GEA Transcript - Seeking Alpha
- 12 days ago - Jazz Pharmaceuticals: A Strong Buy Due To Execution In Oncology - Seeking Alpha
- 13 days ago - Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer - PRNewsWire
- 15 days ago - Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall Survival Benefit - PRNewsWire
- 5 weeks ago - Jazz Pharmaceuticals to Participate in Upcoming Investor Events - PRNewsWire
- 6 weeks ago - Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting - PRNewsWire